Hence, we carried out a retrospective analysis at our centre to investigate the treatment patterns and outcomes in Indian ALK-positive NSCLC patients, with an emphasis on procurement, use, tolerance and outcomes with Crizotinib. Here, ALK is linked to non-small cell lung carcinoma.